Nine subjects with atopic asthma (five male subjects; mean age, 29 years; American Thoracic Society diagnostic criteria for asthma) received inhaled FP, 2,000 ^g/d for 8 weeks. Baseline characteristics are presented in Table 1. No subjects had an exacerbation of asthma or had received corticosteroid therapy within the 3 months prior to the study. Baseline FEV1 for all subjects was > 40% of predicted. All subjects showed both a > 250 mL (and a > 12.5%) increase in FEV1 after treatment with inhaled albuterol this buy tavist online. All subjects demonstrated bronchial hyperreactivity (provocative concentration of histamine causing a 20% fall in fEv-l [PC20] of < 8 mg/mL within 4 weeks of entry to the study). Subjects were considered atopic if they had a history of bronchospasm after allergen exposure and had a positive skin-prick test result to at least one of a panel of common allergens (house dust mite, grass pollen, cat and dog dander, and birch pollen; Table 1). Subjects with other concurrent illness, pregnancy, or lactation were excluded. During the study, no oral corticosteroids were allowed. Rescue inhalers were confined to albuterol by metered-dose inhaler. The protocol was approved by the Ethics Committee at the James Connolly Memorial Hospital, Blanchardstown, Dublin, and by the Irish National Drugs Advisory Board. Written informed consent was obtained from each subject.
Study participants were enrolled in a randomized, doubleblind, placebo-controlled, parallel group trial of high-dose inhaled FP for asthma. The results of this study and comparisons between placebo and steroid treatments have been published elsewhere. Nine subjects with atopic asthma were assigned (in a double-blind fashion) to receive FP, 2,000 ^g/d, via a metered-dose inhaler attached to an aerosol chamber (Volumatic Spacer; Allen and Hanburys; Greenford, UK).
Table 1—Baseline Characteristics of the Nine Subjects Who Completed the Protocol
|Age, yr||Sex||Asthma Duration, yr||Skin-prick Testing*|